



## Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

October 7, 2020

**Stevenage, UK 7 July 2020** — Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.

“It has been a transformational time for Achilles as we progress both our THETIS study in melanoma and our CHIRON study in non-small cell lung cancer through clinical development,” said **Dr Iraj Ali, CEO of Achilles**. “Dan will be a great asset to the team as we grow the Company, broaden our pipeline into new indications and explore future strategic relationships.”

**Dan Hood, Chief Legal Officer of Achilles, added:** “Achilles Therapeutics is at the forefront of transforming cancer treatment by targeting clonal neoantigens to develop personalised T cell therapies. I am delighted to join such an experienced and motivated team on their journey to revolutionising cancer care.”

Dan joins Achilles from Intercept Pharmaceuticals where he was Vice President, Legal with responsibility for all legal matters outside the United States. He has extensive experience as an in-house lawyer, including leadership and business partnering roles within GE Healthcare and Gilead Sciences. Dan has an MA in Law from Cambridge University and is enrolled as a solicitor in England & Wales and Ireland.

— Ends —

### Notes for Editors:

#### About Achilles Therapeutics

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/II studies, the THETIS study in patients with recurrent or metastatic malignant melanoma and the CHIRON study in patients with advanced non-small cell lung cancer (NSCLC). Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUSâ„¢ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.

Achilles was founded in 2016 by lead investor Syncona Ltd and in September 2019 the Company raised Â£100M in an oversubscribed Series B financing led by RA Capital, cornerstoned by Syncona and joined by new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. For further information please visit the Company’s website at: [www.achillestx.com](http://www.achillestx.com)

#### Further information:

##### Achilles Therapeutics

Dr Iraj Ali — Chief Executive Officer

+44 (0)1438 906 906

[media@achillestx.com](mailto:media@achillestx.com)

##### Julia Wilson — Head of Communications

+44 (0)7818 430877

[j.wilson@achillestx.com](mailto:j.wilson@achillestx.com)

##### Consilium Strategic Communications

Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

+44 (0) 203 709 5000

[achillestx@consilium-comms.com](mailto:achillestx@consilium-comms.com)

##### US Investor Relations — Solebury Trout

Lee Stern

+1 646-378-2922

[lstern@troutgroup.com](mailto:lstern@troutgroup.com)